Urolithin A Benefits: What the Research Shows

Urolithin A has become one of the most researched longevity ingredients of the past decade, but the word “benefits” gets thrown around loosely in this category. This guide separates what human trials actually support from what is still early and preclinical — so you can decide what urolithin A can and can't reasonably do for you.

One mechanism behind every benefit: mitophagy

Almost everything attributed to urolithin A traces back to a single cellular process called mitophagy — the body's system for identifying worn-out mitochondria and recycling them so healthier ones can take their place. Mitochondria are the structures that turn food and oxygen into usable energy in nearly every cell, and their quality tends to decline with age as damaged ones accumulate and mitophagy slows.

Urolithin A's role here was first established in foundational preclinical research: Ryu and colleagues (2016, Nature Medicine) showed that urolithin A induced mitophagy, extended lifespan in the worm C. elegans, and improved muscle function in rodents. That was animal and cell work — not proof of human benefit — but it identified the mechanism that later human trials were built around. Understanding this one process is the key to reading every claim below honestly: urolithin A is not a stimulant or a drug that targets a symptom; it works upstream, on the maintenance of the cell's energy machinery. For the underlying biology, see what mitophagy is and our mitochondrial health guide.

Benefit 1: Muscle strength and endurance (human evidence)

This is where urolithin A has the strongest human research, and where the claims are best supported. In a randomized, double-blind, placebo-controlled trial in middle-aged adults, Singh and colleagues (2022, Cell Reports Medicine) reported that four months of daily urolithin A supported improvements in muscle strength and measures of exercise performance versus placebo, alongside favorable mitochondrial biomarkers. The trial included both 500 mg and 1,000 mg daily arms — the basis for the clinically studied range you'll see referenced everywhere.

A separate randomized controlled trial in older adults (Liu/D'Amico et al., 2022, JAMA Network Open) found that urolithin A supported muscle endurance — measured as the number of muscle contractions performed before fatigue — over a comparable period. More recently, the research has extended to athletes: an eight-week randomized, placebo-controlled study in resistance-trained men (2024, Journal of the International Society of Sports Nutrition) examined urolithin A's effects on muscle endurance and markers of inflammation and oxidative stress, and a 2025 trial evaluated running performance, recovery, and mitochondrial biomarkers in highly trained distance runners. Taken together, this is a genuinely growing human evidence base pointing in a consistent direction for muscle and endurance. See urolithin A for muscle for the deep dive.

Benefit 2: Cellular energy and mitochondrial health (human evidence)

The first-in-human study of urolithin A (Andreux et al., 2019, Nature Metabolism) is the anchor for the cellular-energy story. It established that urolithin A was safe and well tolerated at doses up to 1,000 mg per day, and — importantly — that it induced a molecular “signature” in blood and skeletal muscle consistent with improved mitochondrial and cellular health, with the higher dose linked to greater expression of mitochondrial genes.

It's worth being precise about what this means. “Cellular energy” here refers to the health and efficiency of your mitochondria, not a caffeine-like jolt you feel within an hour. Urolithin A supports the machinery that produces energy rather than delivering a stimulant effect, which is why people describe its benefits as gradual and foundational. If you're expecting an instant lift, you'll misjudge it; if you're supporting cellular energy capacity over months, that's the right frame. More on this at urolithin A for energy.

Benefit 3: Immune-cell health and “inflammaging” (newer human evidence)

One of the most interesting recent developments is a 2025 randomized, placebo-controlled trial published in Nature Aging, which examined urolithin A's effect on age-related immune decline. Over roughly a month, the researchers reported that urolithin A supported the mitochondrial health and function of immune cells in midlife adults, nudging markers of aging immune cells toward a more youthful profile — a finding relevant to the concept of “inflammaging,” the low-grade inflammation that tends to rise with age.

This is promising, genuinely human research, but it deserves careful framing: supporting the mitochondrial health of immune cells is a structure/function observation, not evidence that urolithin A treats or prevents any infection or immune disease. It's a marker-level result in healthy adults. Read it as “the cellular-health story extends to immune cells too,” not as a medical claim. Our urolithin A and immune health page covers this with the same caution.

Benefit 4: Emerging and preclinical areas (honest labeling)

Beyond muscle, energy, and immune-cell health, urolithin A is being explored in several other areas — but here the evidence is largely preclinical (cells and animals) rather than proven in humans, and it should be read that way. For example, D'Amico and colleagues (2022, Aging Cell) reported that urolithin A supported joint-cell mitochondrial health and reduced cartilage degeneration in laboratory models of osteoarthritis. Early research is also exploring urolithin A in the context of skin, gut, brain, and cardiovascular biology.

These are legitimate research directions worth watching, but a study in mice or isolated cells does not establish a benefit you can count on as a person. Any brand presenting preclinical findings as proven human benefits is overstating the science. We'd rather tell you honestly: outside of muscle, cellular-energy markers, and the recent immune-cell work, urolithin A's benefits are still being investigated. See our clinical studies page for the full breakdown of what's human versus preclinical.